• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Regeneron's blockbuster eye drug posts weaker sales due to inventory impact

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 02, 2024 at 11:43: AM
via U.S. drugmaker Regeneron Pharmaceuticals Inc (REGN.O) missed Wall Street estimates for quarterly profit on Thursday, hurt by softer sales of its blockbuster eye drug Eylea due to reduction in wholesaler inventory.

article source
 




Top Bottom
Back
Quote